Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dydrogesterone versus drospirenone/ethinylestradiol for lipid metabolism in overweight PCOS
ChiCTR2000039759Phase 4Recruiting
- Sponsor
- Beijing Obstetrics and Gynecology Hospital
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dydrogesterone, drospirenone and ethinyl estradiol in polycystic ovary syndrome (PCOS) (2 arms), sponsored by Beijing Obstetrics and Gynecology Hospital. Primary endpoints: Total cholesterol and Triglycerides. Started Nov 2020; status: recruiting.
02
Drugs
dydrogesteronedrospirenoneethinyl estradiol
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on ChiCTR2000039759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039759.